Partnerships

Co-developing EV-guided precision medicine programs with biopharma partners.

Our clinically validated, AI-enabled platform sits at the heart of our partnerships, unlocking tissue-resolved, multi-omics insights from blood through tissue-specific extracellular vesicles (TS-EVs). We apply these insights with partners across biomarker discovery, patient stratification and companion diagnostic development.

LEARN MORE ABOUT OUR PLATFORM
LEARN MORE ABOUT 
OUR PLATFORM

Value for biopharma partners

Our tissue-resolved, multi-omics platform helps partners focus development on the biology that matters most.

  • Improve trial probability of success

    Identify and enrich for patients most likely to respond to treatment

  • Reduce development costs

    Optimize patient numbers through better population selection

  • Accelerate time to market

    Generate earlier biological insight for faster development decisions

What tissue-resolved
multi-omics unlocks

Our tissue-specific EV approach provides access to biology relevant information directly from the tissue of interest.

  • Tissue-source attribution

    Identify signals from the tissue of interest

  • Active disease biology

    Capture disease-relevant biology from living cells

  • Non-invasive procedure

    Unlock non-invasive access to tissue-relevant biology from blood

Clinical development & Commercialization

Our platform supports precision medicine development across a range of high-value applications, including:

  • Target engagement

    Determine whether a therapy is modulating the intended biology within the tissue of interest

  • MoA validation

    Generate tissue-specific biological evidence to validate and refine therapeutic mechanism of action

  • CDx regulatory capabilities

    Support companion diagnostic development through regulatory strategy and clinical translation

Existing partnerships

Mursla Bio is working with a leading global pharmaceutical company to advance biomarker-guided precision medicine in MASH. The collaboration focuses on pharmacodynamic and mechanism-of-action biomarkers, alongside patient stratification, with a pathway towards companion diagnostic development.

learn more

Partner with us

We are seeking biopharma partners to co-develop EV-guided precision medicine programs, translate biological discoveries into clinical applications and explore new commercial opportunities.

CONTACT US